AssetMark’s Syndax Pharmaceuticals SNDX Stock Holding History
Bought
Maintained
Sold
Other funds holding SNDX
AssetMark's SNDX Position: Q3 2026 in Review
AssetMark reduced its Syndax Pharmaceuticals (SNDX) stake by 38% in Q3 2026, selling an estimated $303 and leaving 25 shares worth $470. The position accounts for ﹤0.01% of the portfolio, ranked #3425.
AssetMark first reported a position in SNDX in Q4 2023 and has held it in 6 quarters since. The position peaked at $934 in Q1 2026. 166 funds tracked by Wall St. Rank hold SNDX as of Q3 2026.
- AssetMark held 25 shares of Syndax Pharmaceuticals worth $470 as of Q3 2026.
- AssetMark sold 15 Syndax Pharmaceuticals shares in Q3 2026, an estimated $303.
- Syndax Pharmaceuticals made up ﹤0.01% of AssetMark's portfolio in Q3 2026, its #3425 holding.
- AssetMark first reported a position in Syndax Pharmaceuticals in Q4 2023 and has held it in 6 quarters since.
- AssetMark's Syndax Pharmaceuticals position peaked at $934 in Q1 2026.
- 166 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q3 2026.
Based on AssetMark's 13F filing for Q3 2026, filed 21 Oct 2026.